Andy Kilianski, Ph.D., Joins QBI as Chief Science and Technology Officer
Quantitative Biosciences Institute Appoints Andy Kilianski, Ph.D., as Chief Science and Technology Officer
Businesswire
Image: Businesswire
The Quantitative Biosciences Institute (QBI) at UCSF has appointed Andy Kilianski, Ph.D., as Chief Science and Technology Officer. Kilianski, a former leader at ARPA-H, brings extensive experience in virology and public health, aiming to enhance QBI's mission in transformative therapies and drug discovery.
- 01Andy Kilianski has over a decade of experience in virology, national security, and translational research.
- 02At ARPA-H, he managed over $1 billion in R&D investments and launched significant programs like APECx and CATALYST.
- 03Kilianski played a key role in the U.S. Department of Defense's COVID-19 Task Force and Operation Warp Speed.
- 04He has a Ph.D. in Microbiology and Immunology and has received multiple awards for his service.
- 05In his new role, he will lead QBI's technology strategy and support the development of spinouts.
Advertisement
In-Article Ad
The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), has appointed Andy Kilianski, Ph.D., as its Chief Science and Technology Officer. Kilianski, who previously served as a Program Manager at the Advanced Research Projects Agency for Health (ARPA-H), brings over a decade of experience in virology and public health. His leadership at ARPA-H included managing a portfolio exceeding $1 billion in research and development, focusing on transformative vaccine and drug development programs. Notably, he contributed to the Department of Defense's COVID-19 Task Force and was instrumental in Operation Warp Speed. Kilianski's academic background includes a Ph.D. from Loyola University Chicago, and he has received several prestigious awards for his contributions to health and national security. In his new role at QBI, he will spearhead technology strategy and industry engagement, leveraging his unique expertise to advance QBI's mission in disease-agnostic drug discovery and pandemic preparedness. Kilianski expressed enthusiasm about joining QBI, highlighting its potential to bridge scientific discovery with impactful health solutions.
Advertisement
In-Article Ad
Kilianski's appointment is expected to strengthen QBI's role in drug discovery and public health, potentially leading to advancements in therapies for various diseases.
Advertisement
In-Article Ad
Reader Poll
What do you think about the appointment of Andy Kilianski at QBI?
Connecting to poll...
Read the original article
Visit the source for the complete story.